George Gemayel

George Gemayel, Ph.D, has served as a member of our Board since 2015. Since 2010, he has served as consultant for several biotechnology companies and venture capital funds. From February 2011 to December 2012, Dr. Gemayel served as Executive Chairman of Syndexa Pharmaceuticals Corp., a privately held drug development company. In 2010, Dr. Gemayel served as Executive Chairman of FoldRx until its acquisition by Pfizer. From June 2008 until November 2009, Dr. Gemayel served as President and CEO of Altus Pharmaceuticals, a publicly traded pharmaceutical company. In November 2009, while Dr. Gemayel was President, CEO, and a director, Altus Pharmaceuticals filed a voluntary petition for relief under Chapter 7 of the U.S. Bankruptcy Code and ceased operations at such time. From 2003 to 2008, he was Executive Vice President at Genzyme Corporation, where he was responsible for Genzyme’s global therapeutics, transplant, renal and biosurgery business. From 2000 to 2003, Dr. Gemayel was employed as Vice President of National Specialty Care for Hoffmann La-Roche, responsible for its U.S. business for dermatology, oncology, transplantation, hepatitis, and HIV. Dr. Gemayel joined Hoffman La-Roche in 1988 and served in various positions of increasing responsibility over his tenure. Dr. Gemayel received his Doctorate in Pharmacy from Saint Joseph University in Beirut, Lebanon and his PhD in Pharmacology from Paris-Sud University in Paris, France. Dr. Gemayel currently serves as Chairman of the Board of Directors of Oxthera AB, Enterome Bioscience SA, and Orphazyme ApS, all privately held companies, as well as a Director of Raptor Pharmaceuticals, Dimension Therapeutics, and Momenta Pharmaceuticals (all NASDAQ-listed companies). He was previously a Director of Adcolor Corporation, a publicly traded company acquired by Cubis Pharmaceuticals, Inc., a Director at Prosena, acquired by Biomarin, a Director at NPS, acquired by Shire, a Director of EpiTherapeutics, acquired by Gilead, and the Chairman of Vascular Magnetics, a privately owned company. Dr. Gemayel’s substantial experience on the Board of Directors of life science and healthcare companies and his over 25 years of experience in the pharmaceutical industry, including management and executive positions spanning the United States, Europe, and the Middle East, qualify him to serve as a director.